Abstract: Although Hodgkin's lymphoma (HL) is highly curable， a minority of patients still presented as  refractory to the frontline treatment or relapse after completion remission.For refractory or relapsed HL (rrHL)， salvage chemotherapy followed by hematopoietic stem cell transplantation  remains the standard of care. PET/CT emerged as a valid measurement for response-adapted treatment strategies in rrHL. Moreover， recent knowledges  on the pathophysiology of rrHL have  promoted the development of novel targeted approach， some of that  have shown promise in the early clinical trials.In this review， we summarize the current treatment strategies for rrHL.

Key words: hodgkin disease, positronemission tomography, molecular targeted therapy